Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|HER2-negative Breast Cancer|ER Positive Breast Cancer
Interventions: DRUG: Alpelisib|DRUG: Tamoxifen|DRUG: Zotatifin|DRUG: Fulvestrant
Sponsor: Stanford University
Collaborators: United States Department of Defense